Search Results - "Fiedler, W.M."

1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors by Mach, N., Belli, C., Fernandez, E., Alsdorf, W., Colombo, I., Dakhel, S., Hemmerle, T., Puca, E., Libbra, C., Mulatto, S., Mock, J.C., Lorizzo, K., Neri, D., Covelli, A., Lauer, U., Hassel, J.C., Stathis, A., Fiedler, W.M., Curigliano, G.

Get full text

182P Exploring cross-compartmental tumor cell plasticity and immunogenicity in serous ovarian cancer by Hell, L.S., Sturmheit, T., Oliveira-Ferrer, L., Ding, Y., Pellens, C., Eylmann, K., Rossberg, M., Fiedler, W.M., Kupper, J., Schmalfeldt, B., Brauneck, F., Wellbrock, J.

Get full text

26O Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors by Curigliano, G., Belli, C., Colombo, I., Ziemer, M., Schmid, S., Dakhel, S., Puca, E., Mulatto, S., Hemmerle, T., Mock, J.C., Lorizzo, K., Neri, D., Covelli, A., Simon, J-C., Lauer, U., Läubli, H., Hassel, J.C., Stathis, A., Fiedler, W.M., Mach, N.

Get full text

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma by Moek, K L, Fiedler, W M, von Einem, J C, Verheul, H M, Seufferlein, T, de Groot, D J, Heinemann, V, Kebenko, M, Menke-van der Houven van Oordt, C W, Ettrich, T J, Rasmussen, E, Bogner, P, Sable, B, Stienen, S, de Vries, E G E

Get full text

Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: ESMO Open Volume 7, Issue 2, April 2022, 100447 by Ochsenreither, S., Fiedler, W.M., Del Conte, G., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., Garralda, A.

Get full text

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors by Ochsenreither, S., Fiedler, W.M., Conte, G.D., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., Garralda, E.

“…The phase I GATTO study (NCT03360734) explored the feasibility, tolerability and preliminary activity of combining gatipotuzumab, a novel humanized monoclonal…”
Get full text

Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] by Ochsenreither, S., Fiedler, W.M., Del Conte, G., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., Garralda, A.

Get full text

PF259 THE COMBINATION OF BEMCENTINIB, A NOVEL, ORAL, SELECTIVE AXL‐INHIBITOR AND LOW‐DOSE CYTARABINE YIELDS DURABLE RESPONSES IN AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY by Loges, S., Heuser, M., Chromik, J., Vigil, C.E., Paschka, P., Re, F., Di Renzo, N., Lemoli, R., Mattei, D., Ben Batalla, I., Hellesøy, M., Micklem, D., Holt, R.J., Schoelermann, J., Lorens, K., Lorens, J.B., Shoaib, M., Aly, H., Brown, A., Fiedler, W.M., Cortes, J.E., Gjertsen, B.T.

“…Background: There is an unmet need in treating AML pts who are unable to tolerate high‐intensity chemo. Treatment of AML pts ≥75 yo is particularly challenging…”
Get full text